The author says that India can learn from Japan's experience in matters of diet and weight loss medicines.

From tackling severe obesity to gaining beauty benefits, weight loss drugs have become a part of popular conversations among doctors and celebrities.

The makers of weight-loss injectable drugs Ozempic/Vegovi (or semaglutide from Novo Nordisk) and Monzaro (tirazeptide from Eli Lilly) are expanding their markets and also focusing on India, says Johann Hari, a Scottish-Swiss author and journalist. Pointing to the experience of Japan. And for India and other countries to find their way through learning, diet and weight loss drugs. (An oral tablet version of semaglutide is available in India.)

“Japan is the only country in the world that became rich without getting fat,” writes Hari in his book “Magic Pill – The extraordinary benefits and disturbing risks of new weight-loss drugs,” where he researches the popularity of weight-loss drugs. . Medicines that cause harm, despite the concerns associated with them.

Obesity has “exploded” around the world, Hari said, and it's not because people are lazy or weak-willed. business Line, calling from London. People become fat when they “go from eating mostly fresh whole foods to eating mostly factory-made foods made with chemicals that don't even mention cooking.” “It’s called cooking.” Hari says.

There are no overweight children in Japan's schools, he says, pointing to their “conscious government design” years ago. “Processed food is strongly discouraged… and (India) can also take that path”, he says, to avoid the current situation in Britain and the United States, where people “are likely to continue to be obese or A difficult choice has to be made. “These are potentially risky drugs.”

“Unknown Unknowns”

Hari writes, “With these weight loss drugs, there are known unknowns related to thyroid cancer, muscle loss, and malnutrition, where we are not yet sure about their scale. But there are also unknown unknowns.”

Novo Nordisk told the author, they monitor the patient safety profile and point to the use of the product in diabetes for 15 years and in weight loss for almost eight years. On the risk of thyroid cancer, it pointed to the European regulatory authority finding no evidence of a link to the drug. Nevertheless, the authors point to the drug's safety leaflet in the US advising against its use in patients with a history of thyroid cancer. Eli Lilly did not respond to the author's questions.

People who stop taking the product may gain weight, making it a lifelong requirement. Hari cautions against exposing children to these products. “We don't currently know about the risks for adults taking these drugs to treat obesity for ten or twenty years – so we don't know at all about the risks for children who potentially take them for eighty years.” Will be taking it till then,” he writes.

  • Also read:'My health, my rights'

Hip replacements and wedding rings

The book says financial analysts expect the pill to impact businesses including fast-food manufacturers, aviation companies, hip and knee device manufacturers, and even wedding ring manufacturers – anticipating a lower obesity population. Is. After getting the injection, Hari advises people with a BMI between 27 and 35 (like himself) to look at the obesity risks versus the drug and “really assess those risks for yourself.”

This is your last free article.

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”